
## Xingnan zheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8633646/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner. Science, 2016, 353, 929-932.	12.6	165
2	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	12.6	134
3	Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes and Development, 2014, 28, 1429-1444.	5.9	111
4	Acetylation modification regulates GRP78 secretion in colon cancer cells. Scientific Reports, 2016, 6, 30406.	3.3	60
5	EgIN2 associates with the <scp>NRF</scp> 1â€ <scp>PGC</scp> 1α complex and controls mitochondrial function in breastÂcancer. EMBO Journal, 2015, 34, 2953-2970.	7.8	58
6	Prolyl hydroxylase-1 regulates hepatocyte apoptosis in an NF-κB-dependent manner. Biochemical and Biophysical Research Communications, 2016, 474, 579-586.	2.1	26
7	USP37 promotes deubiquitination of HIF2α in kidney cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13023-13032.	7.1	24
8	EgIN2 positively regulates mitochondrial function in breast cancer. Molecular and Cellular Oncology, 2016, 3, e1120845.	0.7	4